p.108 抽出テキスト

VTE prophylaxis

Therapeutic doses of LMWH are recommended in patients with MM with previous VTE. I B

Prophylactic doses of LMWH are recommended in patients with MM with VTE-related risk factors (excluding previous VTE) at least during the first 6 months of therapy. I A Recommendation Table 14 for baseline risk assessment and monitoring during combined RAF and MEK inhibitor therapy BP monitoring at each clinical visit and weekly outpatient monitoring during the first 3 months of treatment and monthly thereafter is recommended. I C In patients treated with cobimetinib/vemurafenib, an ECG is recommended at 2 and 4 weeks after initiation of treatment and every 3 months thereafter. I C Baseline echocardiography is recommended in all high- and very high-risk patients scheduled to receive combined RAF and MEK inhibitors. I C Recommendation Table 15 for baseline risk assessment and monitoring during immunotherapy

ECG, NP, and cTn measurements are recommended in all patients before starting ICI therapy. I B

Baseline echocardiography is recommended in high-risk patients before starting ICI therapy. I B

CV assessment is recommended every 6–12 months in high-risk patients who require long-term (.12 months) ICI treatment. I C

Recommendation Table 16 for baseline risk assessment and monitoring during androgen deprivation therapy for prostate cancer Baseline CV risk assessment and estimation of 10-year fatal and non-fatal CVD risk with SCORE2 or SCORE2-OP is recommended in patients treated with ADT without pre-existing CVD. I B

Baseline and serial ECGs are recommended in patients at risk of QTc prolongation during ADT therapy. I B

Annual CV risk assessment is recommended during ADT. I B

Recommendation Table 17 for baseline risk assessment and monitoring during endocrine therapy for breast cancer Baseline CV risk assessment and estimation of 10-year fatal and non-fatal CVD risk with SCORE2 or SCORE2-OP is recommended in BC patients receiving endocrine therapies without pre-existing CVD. I C Annual CV risk assessment is recommended during endocrine therapy in BC patients with high 10-year risk of (fatal and non-fatal) CV events according to SCORE2/SCORE2-OP. I C Recommendation Table 18 for baseline risk assessment and monitoring during cyclin-dependent kinase 4/6 inhibitor therapy

QTc monitoring is recommended at baseline and 14 and 28 days in all patients with cancer receiving ribociclib. I A

QTc monitoring is recommended in patients treated with ribociclib with any dose increase. I B

Recommendation Table 19 for baseline risk assessment and monitoring during ALK and EGFR inhibitors

Baseline CV risk assessment is recommended in patients before ALK inhibitors and EGFR inhibitors. I C

Baseline echocardiography is recommended in all patients with cancer before starting osimertinib. I B

Recommendation Table 20 for baseline risk assessment and monitoring in patients receiving chimeric antigen receptor T cell and tumour-infiltrating lymphocytes therapies

Baseline ECG, NP, and cTn are recommended in all patients with cancer before starting CAR-T and TIL therapies. I C

A baseline echocardiography is recommended in patients with pre-existing CVD before starting CAR-T and TIL therapies. I C

Measurement of NP, cTn, and echocardiography are recommended in patients who develop CRS of ASTCT ≥2. I C

Continued Downloaded from academic.oup.com/eurheartj/article/43/41/4229/6673995 by guest on 07 October 2026